Immudex develops reagents for the detection and characterisation of antigen-specific immune cells. Their Dextramer™ technology enables sensitive analysis of tumour-reactive T cells, CAR-T cells and antigen-specific immune responses, supporting cancer immunotherapy, cell therapy and translational research.
Portfolio
- MHC Dextramer™ reagents for detection of antigen-specific T cells
- Cancer antigen and neoantigen Dextramer™ panels
- CAR Dextramer™ reagents for CAR-T cell detection and characterisation
- dCODE Dextramer™ reagents for single-cell sequencing workflows
- Flow cytometry reagents for immune monitoring
- Reagents for cell therapy and immuno-oncology research
- Custom Dextramer™ reagents for tumour antigen studies
Unravel the complexity of the cellular immune response
Reactions of the immune system to the presence of cancer cells are complex and varied. A diversity of immune cells interact in a collective response, each with different receptor affinities to specific tumor antigens.
Dextramer® reagents can reliably detect and characterize tumor-specific T cells based on the epitope they recognize, including rare or low-affinity CD8+ and CD4+ T cells.
To support precision immune monitoring in cancer, we provide:
- Dextramer® reagents and predefined panels of Dextramer® to detect cancer-specific T-cells by flow cytometry.
- dCODE Dextramer® reagents for analysis of antigen-specific T cells at the single-cell level.
- Klickmer® for detection of antigen-specific B cells.
- Dextramer® for detection of CAR-T cells.
CAR Dextramer® reagents enable direct detection and phenotypic characterisation of CAR-T cells by flow cytometry and single-cell sequencing.
Applications include:
- CAR-T development
- Product characterisation
- Cell persistence studies
- Biomarker discovery
- Translational research
Downloads
